|
|
|
| Efficacy of Terbutaline Combined with Glucocorticoid and Glutathione in the treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Its Effects on Inflammatory Factors Levels |
| LIU Xiaodong, HU Ke |
| People's Hospital of Wuhan University, Hubei Wuhan 430060, China |
|
|
|
|
Abstract Objective: To study the efficacy of terbutaline combined with glucocorticoid and glutathione in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and its effects on inflammatory factors. Methods: 150 patients with AECOPD admitted to the hospital from December 2017 to December 2018 were included in the study. According to the clinical drug regimens, they were divided into group A (tebutaline, n=35) and group B (tebutaline +glucocorticoid, n=61) and group C (tebutaline + glucocorticoid + glutathione, n=54). The treatment effects were observed in the three groups. Results: There was a significant difference in the effective rate of treatment among the three groups (P<0.05), and the effective rate of treatment was the highest in group C, followed by group B, the lowest in group A. After treatment, the scores of cough, expectoration and shortness of breath in groups A, B and C showed downward trends in turn (P<0.05). After treatment, the levels of forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and FEV1/FVC showed upward trend in turn in group A, group B and group C (P<0.05). After treatment, the levels of serum C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) showed downward trends in groups A, B and C (P<0.05). There were no significant differences in the adverse drug reactions among the three groups (P>0.05). Conclusion: Terbutaline combined with glucocorticoid and glutathione can effectively improve lung function, relieve clinical symptoms, reduce the body inflammatory factors, and improve effective rate of treatment in patients with AECOPD, and it has few adverse drug reactions.
|
|
|
|
|
|
[1] 姜轶飞,杨猛,莫伟强.慢性阻塞性肺疾病评估测试评分对AECOPD患者的临床评估价值[J].中国中西医结合急救杂志,2017,24(2):174~176.
[2] 潘嘉宇.还原型谷胱甘肽对慢性阻塞性肺病急性加重期氧化应激的影响[J].中国实验诊断学,2018,22(2):225~228.
[3] 柳涛,蔡柏蔷.慢性阻塞性肺疾病诊断、处理和预防全球策略(2011年修订版)介绍[J].中国呼吸与危重监护杂志,2012,11(1):1~12.
[4] 陈芳,崔敏.维生素D与慢性阻塞性肺疾病的研究进展[J].医药导报,2017,36(1):52~54.
[5] 柴晶晶,朱华栋,于学忠,等.慢性阻塞性肺疾病评估测试对COPD急性加重的有效性评估[J].中国急救医学,2017,37(2):158~163.
[6] 杨振英,王亚坤,周礼清,等.糖皮质激素类联合肾上腺素能β激动剂对慢性阻塞性肺疾病急性加重期患者的疗效分析[J].安徽医药,2018,22(1):151~155.
[7] 嘉婷,缑剑,翟梅,等.抗氧化剂治疗对慢性阻塞性肺病患者的营养和抗氧化状态的影响[J].临床肺科杂志,2017,22(11):2009~2013. |
|
|
|
2020, Vol. 26 
